in our study. While group 1 had a higher exposure to voriconazole and mycophenolate, the SOTRs in group 2 had a greater exposure to azathioprine. The confounding factors, such as use of immunosuppression medications and similar baseline personal risk factors (eg, male sex, age, and prior history of actinic keratosis), underscore the difficulty in predicting which SOTRs will develop a new primary cSCC and which will not. This study's major limitation is its retrospective, singlecenter nature. Fitzpatrick skin phototype information was also not available in our cohort.
Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome
Mogamulizumab is a monoclonal antibody against CC chemokine receptor 4 (CCR4) that has efficacy in patients with relapsed and refractory T-cell lymphomas and has an overall response rate of 36.8% in mycosis fungoides (MF) and Sézary syndrome (SS). 1 Concerns exist regarding the use of mogamulizumab in patients prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) because CCR4 is highly expressed on both malignant and regulatory T cells. Depletion of regulatory T cells following mogamulizumab is thought to augment antitumor response but may also potentiate graft-vs-host disease (GVHD). Significant reduction of peripheral blood and tissue regulatory T cells was observed in patients with cutaneous Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; MF, mycosis fungoides; SS, Sézary syndrome.
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T-cell lymphoma treated with mogamulizumab. 2 Retrospective studies in patients with adult T-cell leukemia/lymphoma have reported that treatment with mogamulizumab prior to transplantation may be associated with an increased risk of severe, steroid-refractory acute GVHD, as well as poor clinical outcomes. 3 We evaluated patients with advanced MF or SS who received mogamulizumab before allo-HSCT.
Methods | We included 8 patients with MF or SS who received mogamulizumab as part of a phase 1/2 clinical trial 1 and subsequently received allo-HSCT. Mogamulizumab was administered weekly as an intravenous infusion for 4 weeks and every 2 weeks thereafter. All patients received a nonmyeloablative allo-HSCT using total-skin electron beam therapy, total lymphoid irradiation, and antithymocyte globulin preparation as a participant in a phase 2 trial at Stanford University (NCT00896493). Graft-vs-host disease prophylaxis consisted of cyclosporine or tacrolimus and mycophenolate mofetil. This study was approved by the Stanford University institutional review board, and patients provided written informed consent.
Results | Patient characteristics are summarized in the Table. The clinical course of each patient is summarized in the Figure. Three-year progression-free survival and overall survival was 37.5% and 50.0%, respectively. One patient developed grade IV gastrointestinal acute GVHD. Notably, this was the only patient who received a peripheral blood stem cell graft from a human leukocyte antigen-mismatched unrelated donor. Another patient developed de novo chronic GVHD, and 1 patient developed donor lymphocyte infusion-related GVHD.
Discussion | In this small, retrospective study of 8 patients with MF or SS who received mogamulizumab prior to allo-HSCT, we observed 1 patient (13%) who developed grade IV acute GVHD. The incidence of acute GVHD in patients with MF or SS patients who underwent allo-HSCT was previously reported as 28% to 50%. 4, 5 Conventional risk factors, including degree of human leukocyte antigen disparity and peripheral blood stem cell graft source, were likely the dominant factors that contributed to acute GVHD in this patient. Another patient developed GVHD after donor lymphocyte infusion, the purpose of which is to enhance graft-vs-lymphoma effects but is also associated with a 30% incidence of GVHD. 6 Prior studies in adult T-cell leukemia/lymphoma suggest that a short interval between the last administration of mogamulizumab and allo-HSCT is associated with a greater risk of severe acute GVHD, possibly related to residual mogamulizumab and its effects on regulatory T-cell depletion. Though the half-life of mogamulizumab is approximately 16 to 18 days, in vivo studies demonstrate that regulatory T cells may be depleted for half a year or longer. 3 Time from last mogamulizumab administration to allo-HSCT in our cohort was more than 200 days, and patients likely had sufficient time to clear mogamulizumab and replete regulatory T cells. No patients were in the high-risk time frame (<50 days) reported in adult T-cell leukemia/ lymphoma studies. 2 In 8 patients with remote exposure to mogamulizumab prior to allo-HSCT, we did not observe a notable increased incidence of grade II to IV acute GVHD. As phase 1/2 1 and re- 
Assessment of Smartphone Application for Teaching Intuitive Visual Diagnosis of Melanoma
The ABCD rule has long been the primary framework for teaching clinicians and patients to differentiate melanomas from benign lesions. However, it remains unclear that such rulebased methods are a substitute for pattern-recognition skills in the diagnosis of skin lesions. 1, 2 Dermatologists develop an innate sense of how melanomas appear after examining thousands of malignant and benign lesions. In contrast, most medical students are relatively disadvantaged by the paucity of their dermatology exposure. Thus, limited experience is the primary barrier to the development of pattern-recognition and intuition as a reliable tool for melanoma diagnosis in nonexperts. 3 To remedy this problem, we developed a novel If given the opportunity, how likely are you to use your learning modality in the future? 3.6 3.4
I think this type of training should be included in the medical curriculum.
3.8 4.0 a Evaluated using 1-5 point scale with 1 indicating "strongly disagree" and 5 indicating "strongly agree."
